Akebia Therapeutics is an ischemia and vascular biology company spun-out of Procter & Gamble and co-founded by Orchard/Sigvion. Their focus is on clinical development of programs for anemia and ischemia related disorders. The lead compound, AKB-6548, is a once daily, oral HIF2 stabilizing agent (HIF-PH inhibitor) in phase 2 clinical trials for chronic anemia. Akebia has raised over $50 million and is in Phase 2 clinical trials.
Co-Investors: Novartis Venture Fund, Triathlon Medical Ventures, Venture Investors, Kearny Venture Partners
Aerpio Therapeutics was spun out of Akebia and is based on two of the programs Orchard helped acquire from P&G. Aerpio is a clinical-stage biotechnology company focused on the development of novel small molecules and monoclonal antibodies for the treatment of vascular disease and enhancement of wound healing.
Co-Investors: Akebia Investors
Nymirum is a drug discovery company with a proprietary platform that targets RNA with small molecules. Drug developers around the world have focused on RNA as one of the most promising new areas of the 21st century. Utilizing small molecules avoids the drug delivery difficulties inherent in nucleic acid-based siRNA and antisense approaches and enables orally available treatments for a broad range of diseases.
Logical Therapeutics, a Boston based company, is developing drugs to treat a variety of medical conditions that are caused by or are associated with excessive inflammation, including various forms of arthritis, obesity and type 2 diabetes mellitus. The Company's lead compound, LT-NS001, is a pro-drug, which is converted in the bloodstream into naproxen, a non-steroidal anti-inflammatory drug (NSAID). Naproxen is widely regarded as the NSAID with the most favorable cardiovascular safety profile among all of the drugs in this class.
Co-Investors: SV Life Sciences, Burrill & Company, Novo A/S
ProNAi Therapeutics is an emerging biopharmaceutical company that has developed an IND approved anti cancer drug candidate with nucleic acids as the basis for the therapy.
Co-Investors: Apjohn Ventures